| Literature DB >> 29520050 |
Ramachandran Rajalakshmi1, Radhakrishnan Subashini2, Ranjit Mohan Anjana2, Viswanathan Mohan2.
Abstract
OBJECTIVES: To assess the role of artificial intelligence (AI)-based automated software for detection of diabetic retinopathy (DR) and sight-threatening DR (STDR) by fundus photography taken using a smartphone-based device and validate it against ophthalmologist's grading.Entities:
Mesh:
Year: 2018 PMID: 29520050 PMCID: PMC5997766 DOI: 10.1038/s41433-018-0064-9
Source DB: PubMed Journal: Eye (Lond) ISSN: 0950-222X Impact factor: 3.775
Fig. 1Remidio Fundus on Phone—retinal imaging
Fig. 2Comparison of diabetic retinopathy (DR) severity between ophthalmologist and EyeArt software grading (n = 296)
Fig. 3Venn diagram showing the overlap comparison of sight-threatening diabetic retinopathy (STDR) between manual (Ophthalmologist) and Software (EyeArtTM) grading (n = 296)
Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and kappa agreement of EyeArt for detection of any varying degrees of DR with ophthalmologist grading as reference standard
| Retinopathy | Sensitivity, % (95% CI) | Specificity, % (95% CI) | PPV | NPV | Kappa | |
|---|---|---|---|---|---|---|
| Any DR | 95.8 (92.9, 98.7) | 80.2 (72.6, 87.8) | 89.7 (85.5, 93.8) | 91.4 (85.7, 97.1) | 0.78 (0.71, 0.86) | <0.001 |
| DME | 97 (91.5, 99.4) | 75.8 (69.7, 81.8) | 67.4 (59.7, 75.0) | 98.0 (94.3, 99.6) | 0.66 (0.58, 0.74) | <0.001 |
| PDR | 78.1 (63.8, 83.3) | 89.8 (86.1, 93.4) | 48.1 (34.5, 61.7) | 97.1 (95.0, 99.2) | 0.53 (0.4, 0.67) | <0.001 |
| STDR | 99.1 (95.1, 99.9) | 80.4 (73.9, 85.9) | 75.3 (68.4, 82.3) | 99.3 (96.3, 100) | 0.75 (0.67, 0.83) | <0.001 |
| RDR | 99.3 (96.1, 99.9) | 68.8 (61.5, 76.2) | 74.6 (68.4, 80.8) | 99.1 (97.2, 100) | 0.67 (0.59, 0.75) | <0.001 |
Any DR diabetic retinopathy (any stage), DME diabetic macular oedema, PDR proliferative diabetic retinopathy, STDR sight-threatening diabetic retinopathy (severe NPDR, PDR and DME), RDR referable diabetic retinopathy (moderate NPDR and above and/or presence of clinically significant macular oedema [CSME])